Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Silver sulfadiazine

Related Products

Hot Products

Name

Silver sulfadiazine

EINECS 244-834-5
CAS No. 22199-08-2 Density 1.496g/cm3
PSA 94.32000 LogP 3.11490
Solubility N/A Melting Point 285 °C (dec.)(lit.)
Formula C10H9AgN4O2S Boiling Point 512.6 °C at 760 mmHg
Molecular Weight 357.141 Flash Point 263.8 °C
Transport Information N/A Appearance solid
Safety 26-36 Risk Codes 36/37/38
Molecular Structure Molecular Structure of 22199-08-2 (Silver sulfadiazine) Hazard Symbols IrritantXi
Synonyms

Silver,(4-amino-N-2-pyrimidinylbenzenesulfonamidato-NN,O1)-;Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt (8CI);Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex;Dermazin;Flamazine;Flammazine;Geben;NSC 625324;Silvadene;Silver 2-sulfanilamidopyrimidine;Silverol;Sulfadiazine silver;

Article Data 7

Silver sulfadiazine Consensus Reports

Silver and its compounds are on the Community Right-To-Know List. EPA Genetic Toxicology Program.

Silver sulfadiazine Standards and Recommendations

OSHA PEL: TWA 0.01 mg(Ag)/m3
ACGIH TLV: TWA 0.01 mg(Ag)/m3

Silver sulfadiazine Specification

The Sulfadiazine silver salt is an organic compound with the formula C10H9AgN4O2S. The IUPAC name of this chemical is silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide. With the CAS registry number 22199-08-2, it is also named as Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt. The product's categories are Ag (Silver) Compounds;Antibiotics for Research and Experimental Use; Biochemistry; Classes of Metal Compounds; Sulfonamides (Antibiotics for Research and Experimental Use); Transition Metal Compounds; Intermediates & Fine Chemicals; Pharmaceuticals; Sulfur & Selenium Compounds. Besides, it is a topical sulfonamide/silver antibacterial used as a topical burn cream on burns, including chemical burns. It prevents the growth of a wide array of bacteria, as well as yeast, on the damaged skin.

Physical properties about Sulfadiazine silver salt are: (1)ACD/LogP: -0.12; (2)#H bond acceptors: 6; (3)#H bond donors: 3; (4)#Freely Rotating Bonds: 2; (5)Polar Surface Area: 83.57 Å2; (6)Flash Point: 263.8 °C; (7)Enthalpy of Vaporization: 78.38 kJ/mol; (8)Boiling Point: 512.6 °C at 760 mmHg; (9)Vapour Pressure: 1.28E-10 mmHg at 25°C.

When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. When you are using it, wear suitable protective clothing. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

You can still convert the following datas into molecular structure:
(1)SMILES: [Ag+].O=S(=O)([N-]c1ncccn1)c2ccc(N)cc2
(2)InChI: InChI=1/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
(3)InChIKey: UEJSSZHHYBHCEL-UHFFFAOYAS
(4)Std. InChI: InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
(5)Std. InChIKey: UEJSSZHHYBHCEL-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo skin 536mg/kg/21W- (536mg/kg) PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) Lancet. Vol. 340, Pg. 126, 1992.
mouse LDLo intraperitoneal 550mg/kg (550mg/kg)   United States Patent Document. Vol. #4020150,
mouse LDLo oral > 10gm/kg (10000mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
mouse LDLo subcutaneous > 10gm/kg (10000mg/kg) LIVER: OTHER CHANGES

BLOOD: CHANGES IN SPLEEN
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
rat LD50 intraperitoneal 126mg/kg (126mg/kg) LIVER: OTHER CHANGES

BLOOD: CHANGES IN SPLEEN

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
rat LD50 oral > 10gm/kg (10000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 637, 1982.
rat LD50 unreported 160mg/kg (160mg/kg)   United States Patent Document. Vol. #4535078,
rat LDLo subcutaneous > 10gm/kg (10000mg/kg) LIVER: OTHER CHANGES

BLOOD: CHANGES IN SPLEEN
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 22199-08-2